GSK to Acquire 10% stake in CureVac for $163M

 GSK to Acquire 10% stake in CureVac for $163M

Shots:

  • GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs
  • CureVac to receive $137M (€120m) as upfront, $34.3 (€30m) as one-time reimbursable payment and is eligible to receive up to $366M (€320m) as development and regulatory milestones, $435M (€380m) as commercial milestones along with royalties on product sales
  • CureVac will lead pre/clinical-development till P-I trial after which GSK will develop & commercialize the therapies. Moreover, CureVAc will receive R&D funding from GSK and will be responsible for the GMP manufacturing of the candidates as well as retain the commercialization rights for all products in selected countries

Click here to read full press release/ article | Ref: GSK | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post